Dr. Chism is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1915 White Ave
Knoxville, TN 37916Phone+1 865-331-2863Fax+1 865-331-2823
Summary
- Dr. Chism is a clinical researcher focused on the development of novel therapeutics for patients with genitourinary malignancies at Vanderbilt – Ingram Cancer Center. His practice is devoted to the care of patients with urological cancers, the design and implementation of clinical trials and correlative science studies in patients with prostate, bladder, kidney and testis cancers, as well the education of trainees.
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2011 - 2014
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 2008 - 2011
- University of Tennessee Health Science Center College of MedicineClass of 2008
- Tulane UniversityMSc, Cell & Molecular Biology, 2003
- Georgetown UniversityB.A., Psychology, 1997
Certifications & Licensure
- TN State Medical License 2015 - 2026
- IN State Medical License 2018 - 2019
- NC State Medical License 2010 - 2017
- GA State Medical License 2014 - 2015
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Merit Award ASCO Cancer Foundation Board of Directors and the 2014 Genitourinary Cancers Symposium Program Committee, 2014
- John William Pope Clinical Fellow Award for outstanding clinical/translational cancer research 2014
- Outstanding Fellow Award North Carolina Oncology Association (NCOA), 2013
- Join now to see all
Clinical Trials
- Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Start of enrollment: 2017 Aug 24
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Start of enrollment: 2017 Apr 28
Publications & Presentations
PubMed
- 1569 citationsFatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y. Wang, Joe-Elie Salem, Justine V. Cohen, Sunandana Chandra, Christian Menzer
JAMA Oncology. 2018-12-01 - 281 citationsTesticular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.Timothy D Gilligan, Daniel W. Lin, Rahul Aggarwal, David D. Chism, Nicholas G. Cost
Journal of the National Comprehensive Cancer Network. 2019-12-01 - 636 citationsIntrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biologyJeffrey S. Damrauer, Katherine A. Hoadley, David D. Chism, Cheng Fan, Christopher J. Tiganelli
Proceedings of the National Academy of Sciences of the United States of America. 2014-02-25
Journal Articles
- Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adreno-Genital Syndrome)Vukina, J, Chism DD, Sharpless J, Raynor M, Milowsky, MI and Funkhouser W, Case Rep Pathol, 1/1/2015
- Mechanisms of acquired resistance to androgen receptor targeting drugs in castration resistant prostate cancerChism D, De Silva D, Whang YE, Expert Review of Anticancer Therapy, 1/13/2014
- Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomesChism, D and Rathmell, WK, Clin Cancer Res, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- LCCC 1406: A Phase II Trial of Palbociclib (PD-332991) in Patients with Metastatic Urothelial Cancer (UC) after Failure of First-Line Chemotherapy.Rose, TL, Alva, AS, Chism, DD, Deal, AM, Kim, WY, and Milowsky, MI, ASCO, 1/1/2016
- Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients.Kardos, J, Melquist, J, Chism, D, Choi, W, Cockerill, K, Paluri, R, Moses, K, Sonpavde, G, McConkey, D, Kim, W, Dinney, C, Milowsky, M, J Clin Oncol, 1/1/2015
- BASE47 gene set predictor as an identifier of "basal-like" subtype of urothelial carcinoma of the bladder in African Americans.Chism DD, Damrauer,JS, Miller A, Milowsky MI, Kim WY, J Clin Oncol, 1/1/2014
- Join now to see all
Press Mentions
- Kidney Cancer Educational Conference at VICC Set Sept. 10September 2nd, 2016
- Genetic Subtypes of Bladder Cancer Reflect Breast Cancer BiologyFebruary 10th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: